From: Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
Cell line | PI3K inhibitor | CI (ED50) | Average CI | Range | Significance |
---|---|---|---|---|---|
H1437 | ZSTK474 | 0,4 | 0,3 | 0,1-0,3 | Strong synergism |
H1437 | PI-103 | 0,2 | Â | Â | Â |
H3122 | ZSTK474 | 0,27 | 0,325 | 0,3-0,7 | Synergism |
H3122 | PI-103 | 0,38 | Â | Â | Â |
MDA-MB231 | ZSTK474 | 0,58 | 0,515 | 0,3-0,7 | Synergism |
MDA-MB231 | PI-103 | 0,45 | Â | Â | Â |
HCT116 | ZSTK474 | 0,4 | 0,635 | 0,3-0,7 | Synergism |
HCT116 | PI-103 | 0,87 | Â | Â | Â |
DFCI032 | ZSTK474 | 0,61 | 0,71 | 0,7-0,85 | Moderate synergism |
DFCI032 | PI-103 | 0,81 | Â | Â | Â |
H358 | ZSTK474 | 0,6 | 0,79 | 0,7-0,85 | Moderate synergism |
H358 | PI-103 | 0,98 | Â | Â | Â |
H2228 | ZSTK474 | 0,87 | 0,885 | 0,85-0,9 | Slight synergism |
H2228 | PI-103 | 0,9 | Â | Â | Â |
A549 | ZSTK474 | 0,9 | 0,93 | 0,90-1,10 | Nearly additive |
A549 | PI-103 | 0,96 | Â | Â | Â |
H441 | ZSTK474 | 1,14 | 1,07 | 0,90-1,10 | Nearly additive |
H441 | PI-103 | 1 | Â | Â | Â |
A431 | ZSTK474 | 1,17 | 1,19 | 1,10-1,20 | Slight antagonism |
A431 | PI-103 | 1,21 | Â | Â | Â |
HCC827 | ZSTK474 | 0,89 | 1,45 | 1,20-1,45 | Moderate antagonism |
HCC827 | PI-103 | 2,01 | Â | Â | Â |
PC9 | ZSTK474 | 1,37 | 1,65 | 1,20-1,45 | Antagonism |
PC9 | PI-103 | 1,93 | Â | Â | Â |
H1518 | ZSTK474 | 1,2 | 1,72 | 1,45-3,3 | Antagonism |
H1518 | PI-103 | 2,24 | Â | Â | Â |
H1975 | ZSTK474 | 2,3 | 1,745 | 1,45-3,3 | Antagonism |
H1975 | PI-103 | 1,19 | Â | Â | Â |